Best Practices for Initiating CDK4/6 Inhibitor Therapy in HR+Metastatic Breast Cancer
Best Practices for Initiating CDK4/6 Inhibitor Therapy in HR+Metastatic Breast Cancer

Arya Mariam Roy, MD

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025
NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACP, Matthew Kurian, MD

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025
Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MD, Vaishali Deenadayalan, MD

Key Insights From the NATALEE Trial 
Key Insights From the NATALEE Trial 

Karissa Britten, MD, Matthew Kurian, MD

Comparative Safety of CDK4/6 Inhibitors: Key AEs and Management Approaches
Comparative Safety of CDK4/6 Inhibitors: Key AEs and Management Approaches

Jasmin Hundal, MD

The Evolving Role of Ribociclib and Optimizing First-Line Treatment in HR+/HER2- Metastatic Breast Cancer 
The Evolving Role of Ribociclib and Optimizing First-Line Treatment in HR+/HER2- Metastatic Breast Cancer 

Nerea Lopetegui-Lia, MD